☆ 4.7 Article

Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab

JOURNAL OF CLINICAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Ophthalmology

Choroidal vascularity index in leptochoroid: A comparative analysis between reticular pseudodrusen and high myopia

Riccardo Sacconi et al.

Summary: This study aimed to investigate the choroidal vascularity index (CVI) in patients with leptochoroid. The results showed that the choroidal vascular and stromal components in eyes with leptochoroid secondary to reticular pseudodrusen (RPD) and high-myopia exhibited different changes. The impairment of the vascular area in RPD eyes might contribute to the lower development of RPD in patients with high myopia.

EYE (2023)

Add to Collection

Article Ophthalmology

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

Tamaki Tamashiro et al.

Summary: This study investigated the changes in subfoveal choroidal thickness after intravitreal injections of brolucizumab in patients with neovascular age-related macular degeneration (AMD). The results showed that brolucizumab significantly reduced the choroidal thickness, especially in treatment-naive AMD patients.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Choroidal structural changes in different intermediate AMD patterns

Pasquale Viggiano et al.

Summary: The study investigated choroidal thickness and choroidal vascularity index in eyes with drusen and RPD compared with healthy individuals using the SD-OCT with EDI system. Results showed significant decreases in both CT and CVI in RPD eyes, but not in eyes with drusen. This suggests that RPD may be associated with altered choroidal vascularity leading to increased risk of late AMD compared to eyes with drusen.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study

Louisa Maria Bulirsch et al.

Summary: Switch to brolucizumab may be a viable treatment option for nAMD patients who are poorly responsive to other anti-VEGF agents, as indicated by the SHIFT study results. However, further long-term analyses are necessary to assess the efficacy and safety of brolucizumab in a routine clinical setting.

BRITISH JOURNAL OF OPHTHALMOLOGY (2022)

Add to Collection

Editorial Material Ophthalmology

Brolucizumab-early real-world experience: BREW study

Ashish Sharma et al.

EYE (2021)

Add to Collection

Article Ophthalmology

Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration

Marco Pellegrini et al.

Summary: This study evaluated choroidal vascular changes in nAMD patients treated with aflibercept injections, showing significant decreases in choroidal thickness and vascularity after treatment, which were significantly correlated with baseline choroidal vascularity index.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

REPEATABILITY OF CHOROIDAL VASCULARITY INDEX MEASUREMENTS USING DIRECTIONAL OPTICAL COHERENCE TOMOGRAPHY IMAGES

Mehmet Giray Ersoz et al.

Summary: This study investigated the repeatability of choroidal vascularity index measurements in directional OCT scans with and without brightness adjustment. The results showed moderate agreement between CVIs obtained from centered and decentered directional scans, emphasizing the importance of standardized beam direction in choroidal vascularity studies.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

Hidetaka Matsumoto et al.

Summary: Loading phase treatment with intravitreal brolucizumab may improve visual acuity and reduce exudative changes in eyes with nAMD associated with type 1 CNV, but careful monitoring for brolucizumab-related intraocular inflammation is necessary.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Ophthalmology

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab Post Hoc Review of HAWK and HARRIER

Jordi Mones et al.

Summary: The analysis of intraocular inflammation cases after brolucizumab injection identified signs of retinal vasculitis with or without retinal vascular occlusion and an associated risk of visual acuity loss.

OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Pravin U. Dugel et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group

Richard F. Spaide et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab

Caroline R. Baumal et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents

Rebecca N. Evans et al.

JAMA OPHTHALMOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration

Jaycob Avaylon et al.

INTERNATIONAL MEDICAL CASE REPORTS JOURNAL (2020)

Add to Collection

Article Ophthalmology

Choroidal Structural Changes in Tubercular Multifocal Serpiginoid Choroiditis

Aniruddha Agarwal et al.

OCULAR IMMUNOLOGY AND INFLAMMATION (2018)

Add to Collection

Article Ophthalmology

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Masahiro Morimoto et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration

Cheolmin Yun et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration

Frank G. Holz et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration

Ursula Schmidt-Erfurth et al.

PROGRESS IN RETINAL AND EYE RESEARCH (2016)

Add to Collection

Article Multidisciplinary Sciences

Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study

Rupesh Agrawal et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Ophthalmology

Luminal and Stromal Areas of Choroid Determined by Binarization Method of Optical Coherence Tomographic Images

Shozo Sonoda et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)

Add to Collection

Article Engineering, Biomedical

Automated estimation of choroidal thickness distribution and volume based on OCT images of posterior visual section

Kiran Kumar Vupparaboina et al.

COMPUTERIZED MEDICAL IMAGING AND GRAPHICS (2015)

Add to Collection

Article Ophthalmology

Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab

Maria Salling Eghoj et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results

Taizo Yamazaki et al.

OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

Abdallah A. Ellabban et al.

CLINICAL OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

The natural history and prognosis of neovascular age-related macular degeneration

Tien Wong et al.

OPHTHALMOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Ranibizumab for neovascular age-related macular degeneration

Philip J. Rosenfeld et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Review Ophthalmology

Neovascular age-related macular degeneration - Natural history and treatment outcomes

D Pauleikhoff

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2005)

Add to Collection

Letter Ophthalmology

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2

NM Bressler

AMERICAN JOURNAL OF OPHTHALMOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.